Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

Centre bans 16 Fixed-Dose Combination drugs over safety concerns

The Centre has imposed an immediate ban on 16 Fixed Dose Combination (FDC) drugs. The Ministry of Health and Family Welfare issued the orders under Section 26A of the Drugs…

Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

Mumbai: In a major crackdown aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has seized an allopathic medicine stock worth over Rs 9.09 lakh from a paediatric…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre bans 16 Fixed-Dose Combination drugs over safety concerns

Centre bans 16 Fixed-Dose Combination drugs over safety concerns

Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

CDSCO constitutes consultancy committee for advice on suo motu disclosure

CDSCO constitutes consultancy committee for advice on suo motu disclosure

Telangana DCA busts illegal API stock, seizes drugs worth Rs 34L

Telangana DCA busts illegal API stock, seizes drugs worth Rs 34L

Zenré Wellness, a New Genre of Mental Care, unveils in Delhi

Zenré Wellness, a New Genre of Mental Care, unveils in Delhi

Raids On Many Hospitals Across Kerala In Organ Trafficking Probe

Raids On Many Hospitals Across Kerala In Organ Trafficking Probe